Company intelligence / Profile preview

Circa Group

Ownership: Private
Employees: ~17
Development stage: Other

Overview

Circa has developed scalable technology to convert waste biomass into high-value bio-based chemicals such as levoglucosenone (LGO) and Cyrene™, with commercial production scaling up at the ReSolute plant in France. Their products are being adopted by major industry players like Merck for greener pharmaceutical synthesis.

Therapeutic areas: Other
Modalities: Small moleculeBio-based solvent
Industry: Non-Drug Biotech

Partnerships

Merck Sharp & Dohme Corp.EU Horizon/Bio-Based Industries Joint Undertaking consortium partners

Beyond the preview

Go deeper on Circa Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Circa Group.

Explore the full profile